Publications

  1. Kottschade LA , McWilliams RR , Markovic SN , Block MS , Villasboas Bisneto J , Pham AQ , Esplin BL , Dronca RS . The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res 2016 Jun; 26 (3):300-3
    View PubMed
  2. Dronca RS , Liu X, Harrington SM, Chen L , Cao S , Kottschade LA , McWilliams RR , Block MS , Nevala WK, Thompson MA , Mansfield AS , Park SS , Markovic SN , Dong H . T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight 2016 May 5; 1 (6)
    View PubMed
  3. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R , Joseph R , Hille D, Xue D, Li XN, Kang SP , Ebbinghaus S, Perrone A, Wolchok JD. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol 2016 May 1; 34 (13):1510-7 Epub 2016 Mar 07
    View PubMed
  4. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R , Joseph RW , Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP , Robert C. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 2016 Apr 19; 315 (15):1600-9
    View PubMed
  5. Ribas A , Hamid O , Daud A , Stephen Hodi F , Wolchok JD , Kefford R , Joshua AM , Patnaik A , Hwu W , Weber JS , Gangadhar TC , Hersey P , Dronca R , Joseph RW , Zarour H , Chmielowski B , Lawrence DP , Algazi A , Rizvi NA , Hoffner B . Association of pembrolizumab with tumor response and survival among patients with advanced melanoma JAMA: Journal of the American Medical Association 2016; 315 (15):1600-9
  6. Dronca R. Turning BiKEs into TriKEs to fight cancer Science Translational Medicine 2016; 8 (328):328ec35
  7. Moser JC, Pulido JS, Dronca RS, McWilliams RR, Markovic SN, Mansfield AS. The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. Melanoma Res. 2015 Feb; 25(1):59-63.
    View PubMed
  8. Dronca RS, Dong H. A gender factor in shaping T-cell immunity to melanoma. Front Oncol. 2015; 5:8. Epub 2015 Feb 02.
    View PubMed
  9. Dronca R. Immunotherapy: Fast and furious: Why all CARs are not made equal. Sci Transl Med. 2015; 7(289):289ec86.
  10. Dronca R. When instability is a good thing. Sci Transl Med. 2015; 7(292):292ec100.
  11. Dronca R. To beam or not to beam. Sci Transl Med. 2015; 7(310):310ec179.
  12. Kottschade LA, Grotz TE, Dronca RS, Salomao DR, Pulido JS, Wasif N, Jakub JW, Bagaria SP, Kumar R, Kaur JS, Morita SY, Moran SL, Nguyen JT, Nguyen EC, Hand JL, Erickson LA, Brewer JD, Baum CL, Miller RC, Swanson DL, Lowe V, Markovic SN. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol. 2014 Dec; 37(6):635-41.
    View PubMed
  13. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. SW, Kang SP, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.
    View PubMed
  14. Dronca RS , Allred JB , Perez DG, Nevala WK, Lieser EA , Thompson M , Maples WJ , Creagan ET , Pockaj BA , Kaur JS , Moore TD, Marchello BT, Markovic SN . Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 2014 Aug; 37 (4):369-76
    View PubMed
  15. Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, Dronca R, Costello B, Frank I. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int. 2014 May; 113(5b):E17-21. Epub 2013 Sep 05.
    View PubMed
  16. Shah DJ, Dronca RS. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc. 2014 Apr; 89(4):504-19.
    View PubMed
  17. Enninga EA, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, Markovic SN. Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. Mayo Clin Proc. 2014 Apr; 89(4):520-35.
    View PubMed
  18. Lowe GC, Saavedra A, Reed KB, Velazquez AI, Dronca RS, Markovic SN, Lohse CM, Brewer JD. Increasing incidence of melanoma among middle-aged adults: an epidemiologic study in Olmsted County, Minnesota. Mayo Clin Proc. 2014 Jan; 89(1):52-9.
    View PubMed
  19. Parikh SA, French CA, Costello BA, Marks RS, Dronca RS, Nerby CL, Roden AC, Peddareddigari VG, Hilton J, Shapiro GI, Molina JR. NUT midline carcinoma: an aggressive intrathoracic neoplasm. J Thorac Oncol. 2013 Oct; 8(10):1335-8.
    View PubMed
  20. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44. Epub 2013 Jun 02.
    View PubMed
  21. Zhang BY, Thompson RH, Lohse CM, Dronca RS, Cheville JC, Kwon ED, Leibovich BC. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int. 2013 Jun; 111(7):1046-53. Epub 2013 Apr 02.
    View PubMed
  22. Zhang B, Malouf J, Young P, Kohli M, Dronca R. Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease. Rare Tumors. 2013; 5(3):e29. Epub 2013 Jul 05.
    View PubMed
  23. Mansfield AS, Nevala WK, Dronca RS, Leontovich AA, Shuster L, Markovic SN. Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. Clin Exp Immunol. 2012 Nov; 170(2):186-93.
    View PubMed
  24. Dronca RS, Leontovich AA, Nevala WK, Markovic SN. Personalized therapy for metastatic melanoma: could timing be everything? Future Oncol. 2012 Nov; 8(11):1401-6.
    View PubMed
  25. Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, Markovic SN. Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc. 2012 Oct; 87(10):976-81.
    View PubMed
  26. Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, Thompson MA, Robinson A, Kottschade LA, Kaur JS, McWilliams RR, Ivanov LV, Croghan GA, Markovic SN. Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed). 2012; 4:958-75. Epub 2012 Jan 01.
    View PubMed
  27. Dronca R, Allred JB, Perez DG, Nevala WK, Lieser EA, Thompson M, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, Moore TD, Marchello BT, Markovic SN. Phase II Study of Temzolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma. Am J Clin Oncol. 2012.
    View PubMed
  28. Jevremovic D, Dronca RS, Morice WG, McPhail ED, Kurtin PJ, Zent CS, Hanson CA. CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res. 2010 Sep; 34(9):1235-8. Epub 2010 Apr 01.
    View PubMed
  29. Dronca RS, Jevremovic D, Hanson CA, Rabe KG, Shanafelt TD, Morice WG, Call TG, Kay NE, Collins CS, Schwager SM, Slager SL, Zent CS. CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. Cytometry B Clin Cytom. 2010; 78 Suppl 1:S35-41.
    View PubMed
  30. Dronca RS, Loprinzi CL, Hartmann LC. Breast cancer risk reduction: SERMs, surgery, and beyond Menopausal Management. 2009 Mar/Apr; 18(2):14-22.
  31. Dronca RS, Steensma D. VTE and mortality associated with recombinant erythropoietin and darbepoetin for treatment of cancer-associated anemia. Nature Clinical Practice Oncology. 2008; 5:504-5.